Menu
Search
|

Menu

Close
X

Epizyme Inc EPZM.OQ (NASDAQ Stock Exchange Global Select Market)

7.55 USD
+0.29 (+3.99%)
As of 1:05 PM EST
chart
Previous Close 7.26
Open 7.27
Volume 34,322
3m Avg Volume 138,007
Today’s High 7.65
Today’s Low 7.27
52 Week High 21.35
52 Week Low 7.21
Shares Outstanding (mil) 79.17
Market Capitalization (mil) 600.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
12
FY17
10
FY16
8
FY15
3
EPS (USD)
FY18
-1.449
FY17
-2.188
FY16
-1.926
FY15
-3.468
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
50.01
22.95
Price to Book (MRQ)
vs sector
3.07
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.04
15.47
LT Debt to Equity (MRQ)
vs sector
0.03
11.13
Return on Investment (TTM)
vs sector
-57.77
13.00
Return on Equity (TTM)
vs sector
-62.20
14.69

EXECUTIVE LEADERSHIP

David Mott
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Robert Bazemore
President, Chief Executive Officer, Director, Since 2015
Salary: $556,200.00
Bonus: $282,967.00
Suzanne Fleming
Principal Financial Officer, Senior Vice President - Finance, Principal Accounting Officer, Treasurer, Since 2018
Salary: --
Bonus: --
Matthew Ros
Chief Operating Officer, Since 2016
Salary: $391,400.00
Bonus: $159,300.00
Jason Fredette
Vice President of Investor Relations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

400 Technology Sq Ste 4
CAMBRIDGE   MA   02139-3584

Phone: +1617.2295872

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

SPONSORED STORIES